H.C. Wainwright says Trevi Therapeutics (TRVI) reported positive topline results of the expected oral nalbuphine human abuse potential study. The results confirm the relatively low abuse potential of nalbuphine and Trevi’s Haduvio for chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough, the analyst tells investors in a research note. H.C. Wainwright’s bullish view on Haduvio is unchanged and it believes yesterday’s share selloff was unwarranted. The stock reacted negatively as some investors fixate on nalbuphine showing some drug-liking, but “that misses the forest for the trees,” the firm contends. It reiterates a Buy rating on Trevi with a $6 price target
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TRVI:
- Trevi Therapeutics announces results from HAP study of oral nalbuphine
- Trevi Therapeutics Reports Q3 2024 Progress and Financials
- Trevi Therapeutics reports Q3 EPS (13c), consensus (12c)
- Stifel says Trevi’s RIVER enrollment completion puts data release in Q1 2025
- Trevi Therapeutics completes enrollment for Phase 2a RIVER trial
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
